Last updated on February 2020

Liquid Biopsy Evaluation and Repository Development at Princess Margaret


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ewing's Family Tumors | Multiple hamartoma syndrome | Uterine Cancer | Meningiomas | Non-Hodgkin's Lymphoma | head and neck cancer | skin cancer | Colon Cancer | Cancer/Tumors | Lung Cancer | Malignant Melanoma | Kidney Cancer | Cancer | Recurrent Ovarian Cancer | Mutation | Multiple Myeloma | Ovarian Cancer | melanoma | Malignant neoplasm of colon | Breast Cancer | Metastatic Melanoma | Bronchial Neoplasm | Cancer (Pediatric) | Leukemia (Pediatric) | Neoplasms | Lynch Syndrome | BRCA1 Mutation | BRCA2 Mutation | Meningioma | Lymphoma | Renal Cancer | leukemia | Lung Neoplasm | Malignant neoplasm of kidney
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Patients with either histological confirmation of a solid tumor or hematological malignancy, OR patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).
  2. Patient must be 18 years old.
  3. All patients must have signed and dated an informed consent form for this LIBERATE study.
  4. If patients are being co-consented for a separate primary research study listed in Appendix I, they must fulfill the eligibility criteria for that separate primary research study. If there is a discrepancy in the eligibility criteria between protocols, the separate primary research study's criteria take precedence.

Exclusion Criteria:

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.